{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:08:07Z","timestamp":1790734087014,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.12.016","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:32:13Z","timestamp":1454459533000},"page":"131-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Targeting the tumour microenvironment in ovarian cancer"],"prefix":"10.1016","volume":"56","author":[{"given":"Jean M.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib2","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of cancer: interactions with the tumor stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2015.12.016_bib4","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2011.0008","article-title":"Epithelial ovarian cancer","volume":"9","author":"Morgan","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.016_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"32","key":"10.1016\/j.ejca.2015.12.016_bib8","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7440","key":"10.1016\/j.ejca.2015.12.016_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11979","article-title":"Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche","volume":"495","author":"Flesken-Nikitin","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2015.12.016_bib11","first-page":"72","article-title":"Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient","volume":"2","author":"Phillips","year":"2012","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.016_bib12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"20","key":"10.1016\/j.ejca.2015.12.016_bib14","doi-asserted-by":"crossref","first-page":"12877","DOI":"10.1073\/pnas.162488599","article-title":"Diversity, topographic differentiation, and positional memory in human fibroblasts","volume":"99","author":"Chang","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF02147594","article-title":"Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction","volume":"27","author":"Gabbiani","year":"1971","journal-title":"Experientia"},{"issue":"4963","key":"10.1016\/j.ejca.2015.12.016_bib17","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1126\/science.2163544","article-title":"Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta","volume":"248","author":"Sieweke","year":"1990","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/carcin\/bgr230","article-title":"Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness","volume":"33","author":"Cai","year":"2012","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib19","first-page":"56","article-title":"Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar","volume":"146","author":"Desmouliere","year":"1995","journal-title":"Am J Pathol"},{"issue":"17","key":"10.1016\/j.ejca.2015.12.016_bib20","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.yexcr.2010.04.032","article-title":"Activation of fibroblasts in cancer stroma","volume":"316","author":"Rasanen","year":"2010","journal-title":"Exp Cell Res"},{"issue":"4726","key":"10.1016\/j.ejca.2015.12.016_bib21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.2996144","article-title":"Wounding and its role in RSV-mediated tumor formation","volume":"230","author":"Dolberg","year":"1985","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.ejca.2015.12.016_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib23","first-page":"482","article-title":"Cancer associated fibroblasts: the dark side of the coin","volume":"1","author":"Cirri","year":"2011","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biocel.2006.11.005","article-title":"Fibroblasts and myofibroblasts: their source, function and role in disease","volume":"39","author":"McAnulty","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.ejca.2015.12.016_bib26","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-07-0684","article-title":"In\u00a0vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors","volume":"67","author":"Granot","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/stemcells.2007-0742","article-title":"Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells","volume":"26","author":"Jeon","year":"2008","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-11-2681","article-title":"Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment","volume":"72","author":"Heller","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.016_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/1541-7786.MCR-11-0175","article-title":"Hedgehog signaling: networking to nurture a promalignant tumor microenvironment","volume":"9","author":"Harris","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm1614","article-title":"Essential role of stromally induced hedgehog signaling in B-cell malignancies","volume":"13","author":"Dierks","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.01.011","article-title":"Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion","volume":"303","author":"Zhang","year":"2011","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1593\/neo.101720","article-title":"Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer","volume":"13","author":"Schauer","year":"2011","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib33","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ijc.11583","article-title":"The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids","volume":"108","author":"Gilead","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2015.12.016_bib34","article-title":"Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer","author":"Mhawech-Fauceglia","year":"2014","journal-title":"Cancer Microenviron"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/IGC.0000000000000414","article-title":"Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach","volume":"25","author":"Itamochi","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib36","first-page":"541","article-title":"CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer","volume":"22","author":"Yao","year":"2009","journal-title":"Oncol Rep"},{"issue":"7353","key":"10.1016\/j.ejca.2015.12.016_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-04-3791","article-title":"Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis","volume":"65","author":"Kiaris","year":"2005","journal-title":"Cancer Res"},{"issue":"4A","key":"10.1016\/j.ejca.2015.12.016_bib39","first-page":"2259","article-title":"Presence of genetic alterations in microdissected stroma of human colon and breast cancers","volume":"21","author":"Wernert","year":"2001","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib40","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/0008-5472.CAN-08-0192","article-title":"Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes","volume":"68","author":"Hawsawi","year":"2008","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.ejca.2015.12.016_bib41","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2015.12.016_bib42","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy+\/\u2212nintedanib for advanced ovarian cancer","volume":"23.8","author":"Du Bois","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann Surg"},{"issue":"21","key":"10.1016\/j.ejca.2015.12.016_bib47","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib48","first-page":"2807","article-title":"Prolonged tumor dormancy by prevention of neovascularization in the vitreous","volume":"36","author":"Brem","year":"1976","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nm0295-149","article-title":"Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression","volume":"1","author":"Holmgren","year":"1995","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/carcin\/21.3.505","article-title":"Tumor angiogenesis: past, present and the near future","volume":"21","author":"Kerbel","year":"2000","journal-title":"Carcinogenesis"},{"issue":"5422","key":"10.1016\/j.ejca.2015.12.016_bib51","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0002-9440(10)64739-6","article-title":"Vasculogenic mimicry and tumor angiogenesis","volume":"156","author":"Folberg","year":"2000","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in\u00a0vivo and in\u00a0vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am J Pathol"},{"issue":"6801","key":"10.1016\/j.ejca.2015.12.016_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"6423","key":"10.1016\/j.ejca.2015.12.016_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in\u00a0vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2015.12.016_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","article-title":"VEGF as a therapeutic target in cancer","volume":"69","author":"Ferrara","year":"2005","journal-title":"Oncology"},{"issue":"7070","key":"10.1016\/j.ejca.2015.12.016_bib57","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.ejca.2015.12.016_bib58","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2015.12.016_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"7204","key":"10.1016\/j.ejca.2015.12.016_bib60","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","article-title":"Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation","volume":"454","author":"Tammela","year":"2008","journal-title":"Nature"},{"issue":"6892","key":"10.1016\/j.ejca.2015.12.016_bib61","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nature00821","article-title":"VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism","volume":"417","author":"Gerber","year":"2002","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib62","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.24028","article-title":"Functional significance of VEGFR-2 on ovarian cancer cells","volume":"124","author":"Spannuth","year":"2009","journal-title":"Int J Cancer"},{"issue":"9698","key":"10.1016\/j.ejca.2015.12.016_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejca.2015.12.016_bib64","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2015.12.016_bib65","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2015.12.016_bib66","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2015.12.016_bib67","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm0603-685","article-title":"Molecular regulation of vessel maturation","volume":"9","author":"Jain","year":"2003","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.016_bib69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib70","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib71","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"issue":"33","key":"10.1016\/j.ejca.2015.12.016_bib72","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.016_bib73","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2011.334","article-title":"Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer","volume":"105","author":"Raja","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.12.016_bib74","series-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. ESMO","author":"Ledermann","year":"2013"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.016_bib75","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"30","key":"10.1016\/j.ejca.2015.12.016_bib79","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2015.12.016_bib80","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.016_bib81","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(11)70244-3","article-title":"Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer","volume":"12","author":"Coleman","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.016_bib83","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.2741\/3438","article-title":"Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications","volume":"14","author":"Li","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"18","key":"10.1016\/j.ejca.2015.12.016_bib84","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/0008-5472.CAN-11-1704","article-title":"DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in\u00a0vivo","volume":"71","author":"Li","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: obligate partners for tumor cell migration, invasion, and metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.onc.1210691","article-title":"Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma","volume":"27","author":"Scavelli","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib87","first-page":"1723","article-title":"Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines","volume":"150","author":"Negus","year":"1997","journal-title":"Am J Pathol"},{"issue":"6917","key":"10.1016\/j.ejca.2015.12.016_bib88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"9255","key":"10.1016\/j.ejca.2015.12.016_bib89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.12.016_bib90","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2002","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2015.12.016_bib91","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. a population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib92","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib93","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","article-title":"Smoldering and polarized inflammation in the initiation and promotion of malignant disease","volume":"7","author":"Balkwill","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.016_bib95","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"issue":"4770","key":"10.1016\/j.ejca.2015.12.016_bib96","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(19910701)68:1<1::AID-CNCR2820680102>3.0.CO;2-K","article-title":"Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. a national biotherapy study group trial","volume":"68","author":"Dillman","year":"1991","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","article-title":"Adoptive cell therapy for the treatment of patients with metastatic melanoma","volume":"21","author":"Rosenberg","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.016_bib99","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","article-title":"Immunotherapy for ovarian cancer: what's next?","volume":"29","author":"Kandalaft","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"issue":"1 Suppl. 4","key":"10.1016\/j.ejca.2015.12.016_bib101","first-page":"S2","article-title":"Prognostic models in melanoma","volume":"24","author":"Halpern","year":"1997","journal-title":"Semin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2015.12.016_bib102","first-page":"3491","article-title":"CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer","volume":"58","author":"Naito","year":"1998","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib103","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z","article-title":"Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma","volume":"74","author":"Marrogi","year":"1997","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.016_bib104","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/0959-8049(94)E0159-2","article-title":"Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma","volume":"30A","author":"Vesalainen","year":"1994","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2015.12.016_bib105","first-page":"5132","article-title":"Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity","volume":"61","author":"Nakano","year":"2001","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2015.12.016_bib106","first-page":"3932","article-title":"Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas","volume":"61","author":"Schumacher","year":"2001","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2015.12.016_bib107","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","article-title":"Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer","volume":"115","author":"Adams","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-009-0750-3","article-title":"A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer","volume":"59","author":"Vlad","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib109","first-page":"501","article-title":"Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes","volume":"1","author":"Fujita","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib110","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib111","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.016_bib112","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.016_bib113","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.ejca.2015.12.016_bib116","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2015.12.016_bib117","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.016_bib118","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib119","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5 Suppl","key":"10.1016\/j.ejca.2015.12.016_bib120","article-title":"Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer","volume":"32","author":"Hamanishi","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejca.2015.12.016_bib121","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5509","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial","volume":"33","author":"Disis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.016_bib122","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.ejca.2015.12.016_bib123","article-title":"PDL1, PDL2, and CD8+ TIL expression in ovarian carcinosarcoma","volume":"33","author":"Peng","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","article-title":"The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages","volume":"66","author":"Allavena","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.016_bib125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0167-5699(92)90008-U","article-title":"The origin and function of tumor-associated macrophages","volume":"13","author":"Mantovani","year":"1992","journal-title":"Immunol Today"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib126","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semcancer.2003.10.001","article-title":"Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors","volume":"14","author":"Mantovani","year":"2004","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.016_bib127","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.016_bib128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2005.10.001","article-title":"Macrophage polarization comes of age","volume":"23","author":"Mantovani","year":"2005","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.016_bib130","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.20030267","article-title":"Regulation of the chemokine receptor CXCR4 by hypoxia","volume":"198","author":"Schioppa","year":"2003","journal-title":"J Exp Med"},{"issue":"21","key":"10.1016\/j.ejca.2015.12.016_bib131","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.016_bib132","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.ejca.2015.12.016_bib133","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/94.15.1134","article-title":"Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice","volume":"94","author":"Huang","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib134","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.016_bib136","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib137","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.016_bib138","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.ejca.2015.12.016_bib139","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1158\/0008-5472.CAN-06-1690","article-title":"All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients","volume":"66","author":"Mirza","year":"2006","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2015.12.016_bib140","first-page":"4441","article-title":"All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination","volume":"63","author":"Kusmartsev","year":"2003","journal-title":"Cancer Res"},{"issue":"7378","key":"10.1016\/j.ejca.2015.12.016_bib141","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.016_bib142","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.016_bib143","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.016_bib144","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.016_bib145","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","article-title":"Tumor-driven evolution of immunosuppressive networks during malignant progression","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res"},{"issue":"2-3","key":"10.1016\/j.ejca.2015.12.016_bib146","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol Res"},{"issue":"6513","key":"10.1016\/j.ejca.2015.12.016_bib147","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/373444a0","article-title":"Fas(CD95)\/FasL interactions required for programmed cell death after T-cell activation","volume":"373","author":"Ju","year":"1995","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.016_bib148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser","year":"2009","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.016_bib149","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"issue":"1-2","key":"10.1016\/j.ejca.2015.12.016_bib150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02700020","article-title":"Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium","volume":"64","author":"Yu","year":"2003","journal-title":"J Neurooncol"},{"issue":"17","key":"10.1016\/j.ejca.2015.12.016_bib151","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T02:54:30Z","timestamp":1567565670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915011600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":151,"alternative-id":["S0959804915011600"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the tumour microenvironment in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}